Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol.

Fecha de publicación: 16/05/2023 Fecha Ahead of Print: 16/05/2023

Autores de IIS La Fe

Marcos Ferrando Serrano

Autor
Ernesto Bosch Aparicio

Autor
Juan Antonio García Velasco

Autor
Esther Santamaría López

Autor

Participantes ajenos a IIS La Fe

Sanchez, Manuel Fernandez
Larsson, Per
Mannaerts, Bernadette

Grupos

Endocrinología Reproductiva e Infertilidad

Leader

José Remohí Giménez

Abstract

PURPOSE: To explore the efficacy and safety of individualized follitropin delta dosing, based on serum anti-Müllerian hormone (AMH) concentration and bodyweight, in a long gonadotropin-releasing hormone (GnRH) agonist protocol. METHODS: Clinical outcomes after one treatment cycle are reported in women with AMH: 5-35 pmol/L. Oocytes were inseminated by intracytoplasmic sperm injection, blastocyst transfer was on Day 5 and remaining blastocysts were cryopreserved. Data collection included live births and neonatal health follow-up for all fresh/frozen transfers performed within one year after treatment allocation. RESULTS: In total, 104 women started stimulation, of whom 101 had oocyte recovery and 92 had blastocyst transfer. The average daily dose of follitropin delta was 11.0 ± 1.6 µg and the duration of stimulation was 10.3 ± 1.6 days. The mean number of oocytes was 12.5 ± 6.4, the mean number of blastocysts was 5.1 ± 3.4, and 85% had at least one good-quality blastocyst. Following mostly single blastocyst transfer (95%), the ongoing pregnancy rate was 43%, the live-birth rate was 43%, and the cumulative live-birth rate was 58% per started stimulation. There were 6 cases of early OHSS (5.8%) graded as mild (n = 3) and moderate (n = 3) and 6 cases of late OHSS (5.8%) graded as moderate (n = 3) and severe (n = 3). CONCLUSION: In this first evaluation of the individualized follitropin delta dosing in a long GnRH agonist protocol, the cumulative live-birth rate was high. A randomized trial comparing follitropin delta in a long GnRH agonist protocol versus in a GnRH antagonist protocol should provide further insight into the efficacy and safety of this treatment option. TRIAL REGISTRATION NUMBER: NCT03564509; June 21, 2018.

Datos de la publicación

ISSN/ISSNe:: 1477-7827, 1477-7827
Tipo:: Article
Páginas:: 45-45
DOI:: 10.1186/s12958-023-01090-w
Factor de Impacto:: 1,198 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Sanchez, Manuel Fernandez:: IVI-RMA Seville, Avenida Americo Vespucio 19, Seville, ES-41092, Spain.

Department of Surgery, Universidad de Sevilla, Seville, ES-41004, Spain.

Department of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, Seville, 41013, ES, Spain.

Instituto de Investigación. Fundacion IVI, Instituto Investigación Sanitaria La Fe, Valencia, ES-46026, Spain.
Larsson, Per:: Global Biometrics, Ferring Pharmaceuticals A/S, Amager Strandvej 405, Kastrup, 2770, Denmark
Serrano, Marcos Ferrando:: Instituto de Investigación. Fundacion IVI, Instituto Investigación Sanitaria La Fe, Valencia, ES-46026, Spain

IVI Bilbao, Bilbao, Valencia, Spain
Bosch, Ernesto:: Instituto de Investigación. Fundacion IVI, Instituto Investigación Sanitaria La Fe, Valencia, ES-46026, Spain

IVI Valencia, Valencia, Spain
Velasco JAG:: Instituto de Investigación. Fundacion IVI, Instituto Investigación Sanitaria La Fe, Valencia, ES-46026, Spain

IVI-RMA Madrid, Madrid, Spain
Lopez, Esther Santamaria:: IVI-RMA Seville, Avenida Americo Vespucio 19, Seville, ES-41092, Spain

Instituto de Investigación. Fundacion IVI, Instituto Investigación Sanitaria La Fe, Valencia, ES-46026, Spain
Mannaerts, Bernadette:: Reproductive Medicine & Maternal Health, Ferring Pharmaceuticals A/S, Amager Strandvej 405, Kastrup, 2770, Denmark